文献速递妇科

醋酸乌利司他治疗症状性肌瘤后子宫腺肌症MRI特征进展

Progression of adenomyosis magnetic resonance imaging features under ulipristal acetate for symptomatic fibroids.
PubMed 文献 · Reprod Biomed Online · 2020-11-26

结果显示,治疗前已识别子宫腺肌症的15例中12例(80.0%)MRI特征进展,治疗前未识别的57例中15例(26.3%)治疗后出现子宫腺肌症。结论提示3个月UPA治疗可能引起子宫腺肌症MRI特征的短期进展或新发。

要点

  • UPA治疗3个月后,已存在子宫腺肌症的MRI特征进展率80.0%(12/15)。
  • 治疗前无子宫腺肌症者中26.3%(15/57)治疗后新出现MRI特征。
  • UPA可能诱发子宫腺肌症肌层内囊性病变的短期进展或新发。

核心结论

  • 每日5 mg UPA治疗3个月可能引起子宫腺肌症MRI特征的短期进展或新发肌层内囊肿。

研究设计与样本

  • 患者在治疗前后分别接受盆腔MRI检查,依据肌层内囊肿、囊内出血灶或结合带厚度>12 mm诊断子宫腺肌症。

主要发现

  • 治疗前已识别子宫腺肌症的15例中,12例(80.0%)治疗后MRI特征进展。
  • 治疗前未识别子宫腺肌症的57例中,15例(26.3%)治疗后出现子宫腺肌症MRI特征。

关键数值与推荐

  • 子宫腺肌症MRI诊断标准:肌层内囊肿和/或囊内出血灶和/或结合带厚度>12 mm。
  • 进展定义:治疗前满足至少一条诊断标准,治疗后结合带厚度增加≥20%和/或肌层内囊肿数量增加。
  • 新发定义:治疗前不满足任何诊断标准,治疗后满足至少一条诊断标准。

临床怎么用

  • 对接受UPA治疗的症状性肌瘤患者,应关注子宫腺肌症MRI特征的短期变化。
  • 治疗前已有子宫腺肌症MRI特征者,UPA治疗后进展风险较高,需随访评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: What is the evolution of adenomyosis on magnetic resonance imaging (MRI) after a 3-month treatment course of daily 5 mg doses of ulipristal acetate (UPA) for symptomatic fibroids? DESIGN: A monocentric prospective pilot study on patients who underwent a 3-month treatment course of UPA for symptomatic fibroids between January 2014 and December 2017. Patients underwent pelvic MRI shortly before (pre-MRI) and after treatment (post-MRI). The diagnosis of adenomyosis on MRI was defined by the observation of intramyometrial cysts and/or haemorrhagic foci within these cystic cavities and/or a thickening of the junctional zone >12 mm. The progression of adenomyosis was defined by the presence of at least one of the aforementioned criteria of adenomyosis on the pre-MRI and by at least one of the following on the post-MRI: (i) increased thickness of the junctional zone ≥20% and/or (ii) increased number of intramyometrial cysts. The appearance of adenomyosis was defined by the absence of the aforementioned criteria of adenomyosis on the pre-MRI and the presence of at least one of these criteria on the post-MRI. RESULTS: Seventy-two patients were included. The MRI features of adenomyosis progressed for 12 of 15 patients (80.0%) for whom adenomyosis was identified on the pre-MRI. An appearance of adenomyosis was identified after treatment for 15 of 57 patients (26.3%) for whom adenomyosis was not identified on the pre-MRI. CONCLUSIONS: A 3-month treatment course of daily 5 mg doses of UPA could provoke a short-term progression or an emergence of typical adenomyosis intramyometrial cysts on MRI examinations.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Calderon L, Netter A, Grob-Vaillant A, et al. Progression of adenomyosis magnetic resonance imaging features under ulipristal acetate for symptomatic fibroids. Reprod Biomed Online. 2020. PMID: 33349531. doi:10.1016/j.rbmo.2020.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。